Medicinal reference book geotar. Humalog: instructions for use Humalog insulin lispro dna recombinant

Humalog®

International nonproprietary name

Insulin lispro

Dosage form

Solution for injection 100 IU/ml 3 ml

Compound

1 ml of solution contains

active substance- insulin lispro 100 IU/ml,

excipients: metacresol, glycerin, zinc oxide, sodium hydrogen phosphate, hydrochloric acid 10%, for pH adjustment, sodium hydroxide 10% solution, for pH adjustment, water for injection.

Description

Transparent colorless liquid

Pharmacotherapeutic group

Drugs for the treatment of diabetes mellitus. Insulins. Insulins and fast-acting analogues. Lispro insulin

ATX code A10AV04

Pharmacological properties

Pharmacokinetics

The onset of action of insulin lispro after subcutaneous administration is approximately 15 minutes, the maximum effect is from 30 to 70 minutes, the duration of action is from 2 to 5 hours. The period of action of insulin lispro may vary depending on the dose, injection site, blood supply, temperature, physical activity of the patient, etc. In the blood, insulin lispro binds to alpha and beta globulins. Normally, binding is only 5-25%, but it can increase significantly in the presence of serum antibodies that appear during treatment. The volume of distribution of insulin lispro is identical to that of humans and is 0.26 - 0.36 l/kg. Metabolism of insulin lispro occurs in the liver and kidneys. In the liver, during one blood circulation, up to 50% of the administered dose is inactivated; in the kidneys, the hormone is filtered in the glomeruli and destroyed in the tubules (up to 30% of the absorbed drug). Less than 1.5% of insulin lispro is excreted unchanged in the urine. The half-life is approximately 1 hour.

Pharmacodynamics

Humalog® is an analogue of human insulin and differs from it only in the reverse sequence of proline and lysine amino acid residues at positions 28 and 29 of the insulin B chain. The main effect of Humalog® is the regulation of glucose metabolism. In addition, all insulins have varying anabolic and anti-catabolic effects on many body tissues. In muscle tissue and other tissues (except for the brain), Humalog® causes rapid intracellular transport of glucose and amino acids, accelerates anabolic processes and inhibits protein catabolism. In the liver, Humalog® increases glucose uptake and glucose stores in the form of glycogen, inhibits gluconeogenesis and accelerates the conversion of excess glucose into fats. The glucodynamic response to Humalog® does not depend on functional failure of the liver and kidneys. The pharmacodynamics of Humalog® in children are identical to those in adults.

Indications for use

diabetes mellitus in adults and children over 2 years of age, in which insulin therapy is indicated to maintain normal glucose homeostasis

stabilization of diabetes mellitus in the early stages

Directions for use and doses

Doses of Humalog® are determined by the doctor depending on the patient's condition. The sensitivity of patients to exogenous insulin varies; 1 unit of subcutaneously administered insulin promotes the absorption of 2 to 5 g of glucose. Humalog® is recommended to be administered no earlier than 15 minutes before meals or shortly after meals 4-6 times a day (monotherapy) or 3 times a day in combination with longer-acting insulin. The administered drug should be at room temperature.

The duration of action of Humalog®, like all other drugs containing insulin, depends on the dose, site of application, blood supply, temperature and physical activity.

Administration modeHumaloga® in adults and childrenindividual! Single and daily doses are adjusted based on the results of repeated studies of glucose levels in the blood and urine throughout the day and depending on the metabolic needs of the patient.

The total daily requirement for Humalog® may vary and is usually 0.5-1.0 IU/kg/day.

Intravenous administration of Humalog® It is carried out as a regular intravenous injection. Intravenous administration of Humalog® can be performed to control blood glucose levels during ketoacidosis, acute illness, or during surgery and in the postoperative period. This requires frequent monitoring of blood glucose levels. Infusion systems with concentrations of 0.1 IU/ml and up to 1 IU/ml of Humalog® in 0.9% sodium chloride solution or 5% dextrose are stable at room temperature for 48 hours.

With subcutaneous infusion of Humalog® using an insulin pump You must strictly follow the instructions included with the pump. The infusion system is changed every 48 hours. If hypoglycemia develops, the infusion is stopped. When using a pump, Humalog® should not be mixed with other insulins.

Subcutaneous injections should be done in the shoulders, hips, buttocks or stomach. Injection sites should be rotated so that the same site is used no more than approximately once a month. When administering Humalog® subcutaneously, care must be taken not to enter a blood vessel when injecting. After the injection, do not massage the injection site. Patients should be taught the correct technique for administering insulin.

Application of Humalog® using an insulin pump.

Only certain insulin pumps can be used for insulin lispro infusion (manufacturers' instructions should be consulted to confirm suitability for your specific pump). You must strictly follow the instructions included with your insulin pumps. An appropriate reservoir and catheter must be used for your insulin pump. The infusion set (tubing and catheter) should be changed according to the instructions in the product information that came with your insulin pump. If a hypoglycemic episode occurs, the infusion should be stopped until the episode resolves. If low blood glucose levels recur or occur, contact your healthcare provider and consider reducing or stopping your insulin infusion. A malfunctioning insulin pump or a clog in your infusion system can cause your glucose levels to rise quickly. If you suspect an interruption in insulin flow, follow the instructions in the product information and, if necessary, notify your doctor. When administering the drug using an insulin pump, Humalog® insulin should not be mixed with other insulin.

Dose preparation

Humalog® cartridges do not require resuspension and can only be used if the contents are a clear, colorless liquid with no visible particles.

Do not use the product if it contains flakes. The design of the cartridges does not allow mixing their contents with other insulins directly in the cartridge itself. Cartridges are not intended to be refilled. You must follow the manufacturer's instructions for each individual pen when refilling the cartridge, attaching the needle, and injecting insulin. To prevent possible transmission of infection, each cartridge should only be used individually by the patient, even if the needle on the pen is replaced with a new one.

Dose administration

Wash your hands.

Select the injection site.

Clean the skin at the injection site with a cotton alcohol swab.

Remove the outer protective cap from the needle.

Secure the leather by pulling it taut or pinching it into a large fold.

Insert the needle and inject.

Remove the needle and apply gentle pressure to the injection site for a few seconds. Do not rub the injection site.

Using the outer needle cap, immediately after administering the drug, unscrew the needle and place it in a safe place.

It is necessary to alternate the injection sites of the drug so that the same area is not used more than once a month.

Do not mix insulin solution in vials with insulin in cartridges.

Side effects

Adverse reactions that occurred more often than in isolated cases are listed according to the following gradation: very often (≥ 10%), often (≥ 1%,< 10%), иногда (> 0,1%, < 1%), редко (> 0,01%, < 0,1%), крайне редко (< 0,01%).

Very often

hypoglycemia is the most common side effect that occurs when administering insulin drugs, including Humalog®. Severe hypoglycemia can lead to loss of consciousness and, in exceptional cases, death.

Often

local allergic reactions(redness, swelling or itching at the injection site) usually goes away within a few days to a few weeks. More often, these reactions are caused by causes unrelated to insulin, such as skin irritation from the cleansing agent or improper injection administration.

Sometimes

lipodystrophy at the site of drug administration.

Rarely

systemic allergic reactions(generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, increased heart rate, increased sweating) are rare, but can be life-threatening. In rare cases of severe allergy to Humalog®, specialized medical care is required. You may need to change your insulin or undergo desensitization.

Contraindications

hypersensitivity to insulin or to one of the components of the drug

hypoglycemia

Drug interactions

® reduce: oral contraceptives, corticosteroids, thyroid hormone preparations, danazol, beta-2 stimulants (ritodrine, salbutamol, terbutaline).

Hypoglycemic effect of Humalog® enhance: oral hypoglycemic drugs, salicylates (eg, aspirin), sulfonamides, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors, certain angiotensin-converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta blockers, octreotide and alcohol.

Beta blockers, clonidine, reserpine may mask manifestation of symptoms of hypoglycemia. With long-term diabetes mellitus, active insulin therapy, and diabetic neuropathy, the symptoms of hypoglycemia may change or be less pronounced.

Incompatibility. The effects of mixing human insulin with animal insulin or human insulin from other manufacturers have not been studied. When using other drugs along with Humalog®, you should consult your doctor.

Combination of Humalog® with pioglitazone:

Cases of heart failure have been reported when pioglitazone is used in combination with insulin, particularly in patients with risk factors for heart failure. This risk should not be forgotten when considering treatment in which the combination of pioglitazone and Humalog® will take place. When using combination therapy, patients should be monitored for signs and symptoms of heart failure, weight gain, and edema. If cardiac symptoms worsen, use of pioglitazone should be stopped.

Special instructions

Humalog® differs from other insulins because it has a unique structure that provides a very rapid onset of action and a short duration of action, so the patient may need to change the dose previously used with other insulins.

Changing insulin should only be done under the supervision of a doctor! Changes in insulin activity, insulin type (for example, Regular, NPH, etc.), type (animal insulin, human insulin, human insulin analogue) and/or production method (DNA recombinant insulin or animal insulin) may lead to the need dose adjustments. When using rapid-acting insulin and basal insulin simultaneously, the patient needs to optimize the dosage of both types of insulin to achieve glucose control throughout the day, including at night and on an empty stomach.

During various illnesses or emotional disorders, the need for insulin may increase.

Insulin requirements may decline with insufficiency of adrenal, pituitary or thyroid function, with renal or liver failure. However, in cases of chronic liver failure, increased insulin resistance may lead to increasing need in insulin.

Dose adjustments may also be necessary with increased physical activity or changes in normal diet. Exercise immediately after eating may increase the risk of hypoglycemia.

Uncorrected hypo- or hyperglycemic reactions can lead to loss of consciousness, coma or death. The use of inadequate dosages of insulin or discontinuation of treatment, especially in insulin-dependent patients, can lead to the development of hyperglycemia and diabetic ketoacidosis, which are potentially fatal conditions.

When used in children, preference should be given to Humalog over soluble insulin only when a rapid onset of insulin action is required.

In cases where patients have increased physical activity or have made changes to their daily diet, dosage adjustments may be necessary. Exercise performed immediately after eating may increase the risk of hypoglycemia.

Pregnancy and lactation

During pregnancy, it is especially important to maintain good control in patients receiving insulin therapy. Insulin requirements generally decrease during the first trimester and increase during the second and third trimesters. People with diabetes are advised to inform their doctor if they are pregnant or planning to become pregnant. During pregnancy, patients with diabetes need careful monitoring of blood glucose levels and general health. In patients with diabetes mellitus, adjustment of the Humalog dose, diet, or both may be necessary during breastfeeding.

Children. Use in children with type 1 diabetes mellitus under 2 years of age and with type 2 diabetes mellitus has not been studied.

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

During hypoglycemia, the patient may experience decreased concentration and slowed psychomotor reactions. This may pose a hazard when driving or operating machinery.

Patients are advised to take precautions to avoid hypoglycemia while driving. This is especially important for patients with few or no warning signs of hypoglycemia or frequent episodes of hypoglycemia. In such cases, the physician must evaluate the appropriateness of the patient's driving.

Overdose

Insulin medications do not have a specific definition of overdose because serum glucose concentrations are the result of complex interactions between insulin levels, glucose levels, and other metabolic processes. Hypoglycemia can occur as a result of a mismatch between the insulin dose and the amount of food eaten and physical activity. Under certain conditions, for example, over a long period of time or with intensive control of diabetes mellitus, the warning symptoms of hypoglycemia may change.

Symptoms: Hypoglycemia may be accompanied by the following symptoms: lethargy, confusion, palpitations, headache, sweating and vomiting.

Treatment: Mild hypoglycemia can usually be treated with oral glucose or sugar. Adjustments to your insulin dose, diet, or physical activity may be necessary. Correction of moderate hypoglycemia can be carried out using intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrates. Severe conditions of hypoglycemia, accompanied by coma, convulsions or neurological disorders, are treated with intramuscular or subcutaneous administration of glucagon or intravenous administration of a concentrated glucose solution. After regaining consciousness, the patient must be given food rich in carbohydrates to avoid re-development of hypoglycemia. Long-term carbohydrate intake and observation may be necessary due to the possibility of recurrent hypoglycemia after apparent clinical recovery. Severe hypoglycemic conditions require emergency hospitalization of the patient.

Release form and packaging

3 ml in cartridges made of transparent, colorless glass. The cartridge is sealed on one side with a stopper and crimped with an aluminum cap, on the other side with a plunger.

5 cartridges are placed in a blister pack made of polyvinyl chloride film and aluminum foil welded to it.

A self-adhesive label is attached to each cartridge.

The contour blister packaging, together with instructions for medical use in the state and Russian languages, is placed in a folding cardboard pack.

Storage conditions

Comments: 0

Comments:

Humalog, the instructions for use indicate this, is used for insulin-dependent and non-insulin-dependent types of diabetes mellitus. This drug is prescribed in many cases when the patient needs to adhere to a specific insulin regimen. Let's look at the main cases when Humalog insulin is used, its contraindications and possible side effects during use.

Pharmacological action of the drug

This is an analogue of human insulin, characterized by a rapid onset and end of the desired effect. Compared to quick-acting drugs, this is the most preferred drug today. This type of insulin is characterized by very rapid absorption from subcutaneous fat.

The main effect of this drug is the regulation of glucose metabolism in the body.

Its anabolic effect is also known. This means that the content of fatty acids and glycogen in muscle tissue increases. The process of protein production in the body intensifies, and the body's need for amino acids increases. At the same time, the intensity of such processes as:

glycogenolysis;
gluconeogenesis;
ketogenesis;
lipolysis;
protein catabolism.

In type 1 or type 2 diabetes, sugar levels drop noticeably after eating. Compared to similar insulin preparations, this action occurs much faster.

The activity of the drug begins after a quarter of an hour if it is administered subcutaneously. Its maximum impact is observed after 30 minutes - 2.5 hours. The total duration of action is up to 4 hours. The half-life of the drug when administered subcutaneously is about an hour.

The onset and intensity of insulin activity may vary over different periods of time among different people. Therefore, there is no universal dosage for this medicine.

The use of Humalog is justified in the following cases:

insulin-dependent diabetes (type 1);
intolerance to other types of insulin and its analogues;
an increase in blood sugar that is not controlled by other types of human insulin;
destruction of insulin if it is administered subcutaneously;
pronounced and persistent resistance to antidiabetic drugs administered orally;
severe malabsorption of other insulin analogues;
hyperglycemia that cannot be treated;
during operations that may disrupt the course of diabetes.

How to use Humalog?

Humalog is administered only in an individually prescribed dosage. The method of introducing the drug into the body is subcutaneous, intramuscular, and in some cases intravenous. Intravenous administration of Humalog is possible only in a hospital setting, since at home this method of injection is associated with certain risks. If Humalog is available in cartridges, then it must be administered only subcutaneously.

Humalog should be taken before meals. It is important to observe the time of its administration: 5–15 minutes before meals. The frequency of injections is from 4 to 6 times a day. If the patient administers additional long-acting insulin, then Humalog is used 3 times a day.

Only the doctor determines the maximum dose of such a drug. Exceeding it is permissible in isolated cases. It is allowed to be combined with other analogues of human insulin, if this mixing is in a syringe. For example, it can be mixed with prolongated insulin. However, we must remember that Humalog must be dialed first. Immediately after mixing these components, you need to give an injection.

If the patient uses a cartridge, then there is no need to add another type of insulin to it. The drug Humalog Mix 25 has the same instructions as other versions of this hormone.

How to administer the drug?

Modern cartridges in which this drug is produced greatly facilitate the administration process. Before using the cartridge, you need to roll it in your palms several times so that the liquid inside has a uniform consistency and color. Vigorous shaking of such a cartridge is unacceptable, because foam may form, interfering with the administration of the medicine.

Insulin Humalog mix 50, the instructions for which provide the same steps before administration, is most suitable for convenient administration using cartridges or syringe pens. The rules for administering the medicine must be followed before each injection. They are as follows:

Always remember the requirements of asepsis and antisepsis recommended by the doctor.
Before injection, you should wash your hands thoroughly with soap.
Prepare the injection site.
Wipe the skin at the injection site.

There is no need to inject insulin into the same place. It is necessary to alternate areas of the body for injections so that they are repeated no more often than every month.

Other routes of administration

Intravenous administration of this drug is also possible. This process should only be carried out in accordance with general clinical guidelines. If the drug is administered intravenously to a patient, more frequent blood glucose measurements are necessary to prevent hypoglycemia.

In addition, the patient can administer Humalog using an insulin pump. In this case, the system must be changed every two days. Strict adherence to aseptic rules when connecting the system is required.

Using an insulin pump requires more careful control of your blood sugar levels. If it happens that the patient develops hypoglycemia, then the administration of Humalog using the pump should be stopped.

The doctor must be informed of all cases of low blood sugar levels and frequently recurring episodes of hypoglycemia so that the dosage can be changed if necessary. If the pump is clogged or malfunctioning, not enough insulin will be supplied to the body. This threatens to increase the amount of sugar.

When does a person's need for insulin change?

The amount of insulin introduced into the human body can vary significantly depending on various factors. All this must be taken into account during insulin therapy. So, a person’s need for the medicine Humalog increases in the following circumstances:

infectious disease (the dose must be adjusted very carefully so that life-threatening hypoglycemia does not develop);
strong emotional stress (chronically elevated sugar may remain if the previous dose is administered);
if a person makes mistakes in his diet and increases the amount of carbohydrates consumed);
if he needs to take drugs that have additional hyperglycemic activity (increasing the dose of the drug in such cases must be done very carefully);
during pregnancy in the 2nd and 3rd trimester.

A decrease in the need for insulin is observed in the following diseases and conditions:

acute or chronic renal failure;
a significant reduction in the amount of carbohydrates in the patient’s food intake;
increased physical activity;
additional intake of medications that have a hypoglycemic effect;
during the 1st trimester of pregnancy;
during childbirth and immediately after it.

Interaction with medications and alcohol

Patients who are taking other medications that affect blood sugar levels should be especially careful. The following medications additionally reduce blood sugar levels:

MAO inhibitors;
β-blockers;
sulfa drugs.

Medicines such as Clonidine, Reserpine, and β-blockers mask the symptoms of low blood sugar. The following medications, on the contrary, reduce the hypoglycemic effect of Humalog:

oral contraceptives;
glucocorticosteroids;
thyroid hormone preparations;
thiazide diuretics;
tricyclic antidepressants.

Alcohol intake during insulin therapy leads to potentiation of the hypoglycemic effect.

Features of administration during pregnancy

Pregnant women need to be especially careful when injecting any type of insulin. The results of modern clinical studies show that there are no undesirable effects when this drug is used correctly.

During pregnancy, patients should carefully monitor their blood glucose levels. This also applies to cases of gestational diabetes. You must carefully follow all your doctor's recommendations, as you may have to change the dosage depending on the trimester of pregnancy.

If a woman has diabetes, is planning a pregnancy and is taking Humalog, she must inform her doctor about this. In this case, you will have to change your insulin treatment regimen.

Side effects and contraindications

When treated with Humalog, some side effects may occur. You need to carefully study them and pay attention to the state of your health in time. So, Humalog is capable of causing the following undesirable effects in the human body:

Sweating.
Pallor of the skin.
Increased heart rate.
Tremor.
Some degrees of sleep disturbance are possible.
Impaired consciousness, and sometimes its complete loss, associated with severe hypoglycemia.
Deterioration of refraction, which is manifested in deterioration of vision.
Allergic reactions (very rare).
Decrease in the amount of fat in subcutaneous adipose tissue.

An overdose occurs when the patient calculates the dose incorrectly. The main signs of an overdose are weakness, nausea, headache, increased heart rate, and clouding of consciousness. Treatment for this condition is the same as for hypoglycemia. It can be quickly stopped by taking quickly digestible carbohydrates or intravenously administering a glucose solution (in a medical facility).

Severe cases of hypoglycemia are treated with intramuscular or subcutaneous administration of glucagon. If there is no reaction to glucagon, then dextrose is administered in the same way. When the patient's consciousness returns, he needs to be given carbohydrate food. If the symptoms of overdose recur frequently, then it is possible to adjust the diet by increasing the amount of carbohydrates.

Storage features and composition of the medicine

1 ml of the drug contains 40 units of an analogue of human insulin. Available in bottles containing 10 ml of solution. It can also be in 1.5 ml cartridges. Insulin should be stored in the refrigerator. Optimal temperature indicators are 2–5ºС. It cannot be frozen, as this will cause it to lose its properties.

An open bottle can also be stored at room temperature. However, care must be taken to ensure that he does not remain in such conditions for longer than 28 days. The medicine should be protected from direct sunlight. Do not use insulin if the solution is cloudy or thickened. A change in color or the presence of foreign objects in it indicates that the drug is unsuitable for further use.

So, the drug Humalog is used only in the treatment of diabetes. The drug should be administered exactly as prescribed by the doctor, taking into account the patient’s condition, physical activity, taking other medications and other factors.

Thank you for your feedback

Comments

Megan92 () 2 weeks ago

Has anyone managed to completely cure diabetes? They say it is impossible to completely cure...

Daria () 2 weeks ago

I also thought it was impossible, but after reading this article, I had long since forgotten about this “incurable” disease.

Megan92 () 13 days ago

Daria () 12 days ago

Megan92, that’s what I wrote in my first comment) I’ll duplicate it just in case - link to article.

Sonya 10 days ago

Isn't this a scam? Why do they sell on the Internet?

Yulek26 (Tver) 10 days ago

Sonya, what country do you live in? They sell it on the Internet because stores and pharmacies charge outrageous markups. In addition, payment is only after receipt, that is, they first looked, checked and only then paid. And now they sell everything on the Internet - from clothes to TVs and furniture.

Editor's response 10 days ago

Sonya, hello. This drug for the treatment of diabetes mellitus addiction is indeed not sold through the pharmacy chain in order to avoid inflated prices. Currently you can only order from official website. Be healthy!

INSTRUCTIONS for medical use of the drug

HumALOG®

HUMALOG®

Trade name

Humalog®

International nonproprietary name

Insulin lispro

Dosage form

Solution for injection 100 IU/ml 3 ml

1 ml of solution contains

active substance - insulin lispro 100 IU/ml,

excipients: metacresol, glycerin, zinc oxide, sodium hydrogen phosphate, hydrochloric acid 10% for pH adjustment, sodium hydroxide 10% solution for pH adjustment, water for injection.

Description

Transparent colorless liquid

Pharmacotherapeutic group

Drugs for the treatment of diabetes mellitus. Fast-acting insulins and analogues.

ATS code A10AV04

Pharmacological properties

Pharmacokinetics

Pharmacodynamics

Humalog® is an analogue of human insulin and differs from it only in the reverse sequence of proline and lysine amino acid residues at positions 28 and 29 of the insulin B chain. The main effect of Humalog® is the regulation of glucose metabolism. In addition, all insulins have different anabolic and anti-catabolic effects on many tissues of the body. In muscle tissue and other tissues (except for the brain), Humalog® causes rapid intracellular transport of glucose and amino acids, accelerates anabolic processes and inhibits protein catabolism. In the liver, Humalog® increases the absorption of glucose and glucose reserves in the form of glycogen, inhibits gluconeogenesis and accelerates the conversion of excess glucose into fats. The glucodynamic response to Humalog® is independent of functional liver and kidney failure. The pharmacodynamics of Humalog® in children are identical to those in adults.

Indications for use

diabetes mellitus in adults and children over 3 years of age, in which insulin therapy is indicated to maintain normal glucose homeostasis

stabilization of diabetes mellitus in the early stages

Directions for use and doses

Doses of Humalog® are determined by the doctor depending on the patient’s condition. The sensitivity of patients to exogenous insulin varies; 1 unit of subcutaneously administered insulin promotes the absorption of 2 to 5 g of glucose. Humalog® is recommended to be administered no earlier than 15 minutes before meals or shortly after meals 4-6 times a day (monotherapy) or 3 times a day in combination with a longer-acting insulin. The administered drug should be at room temperature.

The mode of administration of Humalog® for adults and children is individual! Single and daily doses are adjusted based on the results of repeated studies of glucose levels in the blood and urine during the day and depending on the metabolic needs of the patient.

The total daily requirement for Humalog® may vary and is usually 0.5-1.0 IU/kg/day.

Intravenous administration of Humalog® is carried out as a regular intravenous injection. Intravenous administration of Humalog® can be performed to control blood glucose levels during ketoacidosis, acute illness, or during surgery and in the postoperative period. This requires frequent monitoring of blood glucose levels. Infusion systems with concentrations of 0.1 IU/ml and up to 1 IU/ml of Humalog® in 0.9% sodium chloride solution or 5% dextrose are stable at room temperature for 48 hours.

When infusing Humalog® subcutaneously using an insulin pump, you must strictly follow the instructions included with the pump. The infusion system is changed every 48 hours. If hypoglycemia develops, stop the infusion. When using a pump, Humalog® should not be mixed with other insulins.

Subcutaneous injections should be given in the shoulders, thighs, buttocks, or abdomen. Injection sites should be alternated so that the same site is used no more than approximately once a month. When administering Humalog® subcutaneously, care must be taken to avoid hitting a blood vessel during injection. After the injection, do not massage the injection site. Patients should be taught the correct technique for administering insulin.

Dose preparation

Humalog® cartridges do not require resuspension and can only be used if the contents are a clear, colorless liquid with no visible particles.

Do not use the drug if it contains flakes. The design of the cartridges does not allow mixing their contents with other insulins directly in the cartridge itself. Cartridges are not intended to be refilled. You must follow the manufacturer's instructions for each individual pen when refilling the cartridge, attaching the needle, and injecting insulin.

Dose administration

Wash your hands.

Select the injection site.

Clean the skin at the injection site with a cotton alcohol swab.

Remove the outer protective cap from the needle.

Secure the leather by pulling it taut or pinching it into a large fold.

Insert the needle and inject.

Remove the needle and apply gentle pressure to the injection site for a few seconds. Do not rub the injection site.

Using the outer needle cap, immediately after administering the drug, unscrew the needle and place it in a safe place.

It is necessary to alternate the injection sites of the drug so that the same area is not used more than once a month.

Do not mix insulin solution in vials with insulin cartridges.

Side effects

Very often

Hypoglycemia is the most common side effect that occurs with the administration of insulin preparations, including Humalog®. Severe hypoglycemia can lead to loss of consciousness and, in exceptional cases, death.

local allergic reactions (redness, swelling or itching following injection) usually subside within a few days to several weeks. More often, these reactions are caused by causes unrelated to insulin, such as skin irritation from the cleansing agent or improper injection.

lipodystrophy at the injection site.

systemic allergic reactions (generalized itching, difficulty breathing, shortness of breath, decreased blood pressure, increased heart rate, increased sweating) occur rarely, but can be life-threatening. In rare cases of severe allergy to Humalog®, specialized medical care is required. You may need to change your insulin or undergo desensitization.

Contraindications

hypersensitivity to insulin or to one of the components of the drug

hypoglycemia

Drug interactions

The hypoglycemic effect of Humalog® is reduced by: oral contraceptives, corticosteroids, thyroid hormone preparations, danazol, beta-2 stimulants (ritodrine, salbutamol, terbutaline).

The hypoglycemic effect of Humalog® is enhanced by: oral hypoglycemic drugs, salicylates (for example, aspirin), sulfonamides, monoamine oxidase inhibitors (MAO), selective serotonin reuptake inhibitors, certain angiotensin-converting enzyme inhibitors (captopril, enalapril), angiotensin II receptor blockers, beta-blockers, octreotide, and alcohol.

Beta-blockers, clonidine, reserpine can mask the manifestation of symptoms of hypoglycemia. With long-term diabetes mellitus, active insulin therapy, and diabetic neuropathy, the symptoms of hypoglycemia may change or be less pronounced.

Incompatibility. The effects of mixing human insulin with animal insulin or human insulin from other manufacturers have not been studied. When using other drugs along with Humalog®, you should consult your doctor.

Special instructions

Changing insulin should only be done under the supervision of a doctor! Changes in insulin activity, insulin type (for example, Regular, NPH, etc.), type (animal insulin, human insulin, human insulin analogue) and/or production method (DNA recombinant insulin or animal insulin) may lead to the need for dose adjustment. When using rapid-acting insulin and basal insulin simultaneously, the patient needs to optimize the dosage of both types of insulin to achieve glucose control throughout the day, including at night and on an empty stomach.

During various illnesses or emotional disorders, the need for insulin may increase.

The need for insulin may decrease with insufficiency of the adrenal glands, pituitary gland or thyroid gland, with renal or liver failure. However, in cases of chronic liver failure, increased insulin resistance may lead to an increased need for insulin.

Dosage changes may also be necessary with increased physical activity or a change in normal diet. Exercise immediately after eating may increase the risk of hypoglycemia.

When used in children, preference should be given to Humalog® over soluble insulin only when a rapid onset of insulin action is required.

Pregnancy and lactation

During pregnancy, it is especially important to maintain good control in patients receiving insulin therapy. Insulin requirements usually decrease during the first trimester and increase during the second and third trimesters. Patients with diabetes are advised to inform their doctor if they are pregnant or planning a pregnancy. During pregnancy, patients with diabetes need careful monitoring of blood glucose levels and general health. In patients with diabetes mellitus, adjustment of the Humalog dose, diet, or both may be necessary during breastfeeding.

Children. Use in children with type 1 diabetes mellitus under 3 years of age and with type 2 diabetes mellitus has not been studied.

Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous mechanisms

During hypoglycemia, the patient may experience decreased concentration and slowed psychomotor reactions. This may pose a hazard when driving a vehicle or operating machinery.

Patients are advised to take precautions to avoid hypoglycemia while driving. This is especially important for patients with little or no warning signs of hypoglycemia or frequent episodes of hypoglycemia. In such cases, the doctor should evaluate the advisability of driving a car by the patient.

Overdose

Insulin drugs do not have a specific definition of overdose, since the concentration of glucose in the blood serum is the result of a complex interaction between the levels of insulin, glucose and other metabolic processes. Hypoglycemia can occur as a result of excess insulin activity relative to food intake and energy expenditure. Under certain conditions, for example, with a long duration or with intensive control of diabetes mellitus, the warning symptoms of hypoglycemia may change.

Symptoms: Hypoglycemia may be accompanied by the following symptoms: lethargy, confusion, palpitations, headache, sweating and vomiting.

Treatment: Mild hypoglycemia can usually be treated with oral glucose or sugar. Adjustments to your insulin dose, diet, or physical activity may be necessary. Correction of moderate hypoglycemia can be carried out using intramuscular or subcutaneous administration of glucagon, followed by oral carbohydrate intake. Severe conditions of hypoglycemia, accompanied by coma, convulsions or neurological disorders, are treated with intramuscular or subcutaneous administration of glucagon or intravenous administration of a concentrated glucose solution. After regaining consciousness, the patient must be given food rich in carbohydrates to avoid re-development of hypoglycemia. Long-term carbohydrate intake and observation may be necessary due to the possibility of recurrent hypoglycemia after apparent clinical recovery. Severe hypoglycemic conditions require emergency hospitalization of the patient.

Release form and packaging

3 ml are poured into transparent colorless glass cartridges, sealed with rubber stoppers and rolled up with aluminum caps.

Rp: Humalog 100 ME - 10 ml
D.t.d: No. 2 in amp.
S: pc, dose prescribed by endocrinologist.

Pharmacological action

An analogue of human insulin, it differs from it in the reverse sequence of proline and lysine amino acid residues in positions 28 and 29 of the insulin B chain. Compared to short-acting insulin preparations, insulin lispro is characterized by a faster onset and end of the effect, which is due to increased absorption from the subcutaneous depot due to the preservation of the monomeric structure of insulin lispro molecules in solution. The onset of action is 15 minutes after subcutaneous administration, the maximum effect is between 0.5 hours and 2.5 hours; duration of action - 3-4 hours.

Directions for use

For adults: Installed individually. Insulin lispro is administered subcutaneously, intramuscularly and intravenously 5-15 minutes before meals. A single dose is 40 units; excess is allowed only in exceptional cases. In monotherapy, insulin lispro is administered 4-6 times, in combination with long-acting insulin preparations - 3 times.

Indications

Diabetes mellitus type 1 (insulin dependent), incl. with intolerance to other insulin drugs, with postprandial hyperglycemia that cannot be corrected by other insulin drugs, acute subcutaneous insulin resistance (accelerated local degradation of insulin). Diabetes mellitus type 2 (non-insulin dependent): with resistance to oral hypoglycemic agents, as well as with impaired absorption of other insulin drugs, uncorrectable postprandial hyperglycemia, during operations, intercurrent diseases.

Contraindications

Hypoglycemia, increased sensitivity to insulin drugs.

Side effects

Possible: hypoglycemia (pallor, increased sweating, palpitations, tremor, sleep disturbances, neurological disorders), hypoglycemic precoma and coma, transient refractive errors (more likely in patients who have not previously received insulin). Rarely: allergic reactions, lipodystrophy.

Release form

Solution for injection (cartridges) 100 IU/ml - 3 ml

ATTENTION!

The information on the page you are viewing is created for informational purposes only and does not in any way promote self-medication. The resource is intended to provide healthcare workers with additional information about certain medications, thereby increasing their level of professionalism. Use of the drug " Insulin lispro“mandatorily requires consultation with a specialist, as well as his recommendations on the method of use and dosage of the medicine you have chosen.

The high-quality French drug insulin Humalog has proven its superiority over its analogues, which is achieved through the optimal combination of the main active ingredient and excipients. The use of this insulin greatly simplifies the fight against hyperglycemia in patients suffering from diabetes.

Description of insulin Humalog

Humalog short-acting insulin is manufactured by the French company Lilly France, and its standard release form is a clear and colorless solution enclosed in a capsule or cartridge. The latter can be sold either as part of an already prepared KwikPen syringe pen, or separately, five 3 ml ampoules in a blister. An alternative is the Humalog Mix series of drugs, produced in the form of a suspension for subcutaneous administration, while regular Humalog can also be administered intravenously.

The main active ingredient of Humalog is insulin lispro - a two-phase drug at a concentration of 100 IU per 1 ml of solution, the effect of which is regulated by the following additional components:

glycerol;
metacresol;
zinc oxide;
sodium hydrogen phosphate heptahydrate;
hydrochloric acid solution;
sodium hydroxide solution.

From the point of view of the clinical and pharmacological group, Humalog belongs to analogues of short-acting human insulin, but differs from them in the reverse sequence of a number of amino acids. The main function of the drug is to regulate the absorption of glucose, although it also has anabolic properties. Pharmacologically, it acts as follows: in muscle tissue it stimulates an increase in the level of glycogen, fatty acids and glycerol, and also increases the concentration of proteins and the consumption of amino acids by the body. At the same time, processes such as glycogenolysis, gluconeogenesis, lipolysis, protein catabolism and ketogenesis slow down.

Studies have shown that in patients with both types of diabetes, increased sugar levels decrease noticeably faster after eating a meal if Humalog is used instead of other soluble insulins.

It is important to remember that if a diabetic is receiving short-acting insulin and basal insulin at the same time, the dosage of both the first and second drugs will need to be adjusted to achieve the best result. Despite the fact that Humalog is a short-acting insulin, the final duration of its action is determined by a number of individual factors for each patient:

dosage;
injection site;
body temperature;
physical activity;
quality of blood supply.

Separately, it is worth noting the fact that Humalog insulin is equally effective both when used by adult diabetics and when used in the treatment of children or adolescents. What remains unchanged is that the effect of the drug does not depend on the probable presence of renal or liver failure in the patient, and when combined with high doses of sulfonylurea, the level of glycated hemoglobin is noticeably reduced. Overall, there has been a noticeable reduction in the incidence of nocturnal hypoglycemia, which diabetics often suffer from if they do not take the right medications.

Important to know! Pharmacies have been deceiving me for so long! A diabetes cure has been found that...

The characteristics of Humalog insulin, expressed in numbers, look like this: the onset of action is 15 minutes after injection, the duration of action is from two to five hours. On the one hand, the period of effective operation of the drug is shorter than that of conventional analogues, and on the other hand, it can be used only 15 minutes before a meal, and not 30–35, as is the case with other insulins.

Indications for use of the drug

Insulin Humalog is intended for all patients suffering from hyperglycemia and requiring insulin therapy. We can talk about both type 1 diabetes mellitus, which is an insulin-dependent disease, and type 2 diabetes, in which the blood sugar level increases periodically after eating a meal containing carbohydrates.

Short-acting insulin Humalog will be effective at any stage of the disease, as well as for patients of both sexes and all ages. Its combination with intermediate- and long-acting insulins, approved by the attending physician, is considered effective therapy.

Contraindications and side effects

There are only two categorical contraindications to the use of Humalog: individual intolerance to one or another component of the drug and chronic hypoglycemia, in which the glucose-lowering drug will only intensify negative processes in the body. However, you need to take into account a number of features and instructions when using this insulin:

studies have not shown any negative effects of Humalog on pregnancy and the health of the fetus (and newborn baby);
Insulin therapy is indicated for those pregnant women who suffer from insulin-dependent or gestational diabetes, and in this context it should be remembered that the need for insulin tends to decrease in the first trimester and then increase in the second and third trimesters. After childbirth, this need may decrease sharply, which must be taken into account;
when planning a pregnancy, a woman with diabetes should consult with her doctor, and in the future she will need careful monitoring of her condition;
There may be a need to adjust the dosage of Humalog during breastfeeding, as well as dietary adjustments;
in diabetics with renal or liver failure, faster absorption of Humalog is observed compared to other insulin analogues;
any changes in insulin therapy require observation by a doctor: switching to a different type of insulin, changing the brand of the drug, changing physical activity.

It must be remembered that intensive insulin therapy can, over time, lead to nonspecific or less pronounced symptoms of advancing hypoglycemia (this also applies to the patient switching from animal insulin to Humalog). It is also important to consider the fact that both excessive doses of the drug and abrupt cessation of its use can lead to hyperglycemia. A diabetic's need for insulin tends to increase when infectious diseases or stress are added to diabetes.

As for side effects, the active ingredient of the drug can lead to hypoglycemia, while the combination of other auxiliary agents in some cases causes:

local allergic reactions (redness or itching at the injection site);
systemic allergic reactions (generalized itching, urticaria, fever, edema, tachycardia, decreased blood pressure, increased sweating);
lipodystrophy in the injection area.

Finally, an overdose of Humalog causes severe hypoglycemia with all the ensuing consequences: weakness, increased sweating, heart rhythm disturbances, headache and vomiting. Hypoglycemic syndrome is relieved by standard measures: ingestion of glucose or another sugar-containing product.

Instructions for use of insulin Humalog

The use of Humalog begins with calculating the dose, which is individually determined by the attending physician depending on the diabetic’s need for insulin. This medicine can be administered either before or after meals, although the first option is more preferable. It is imperative to remember that the solution should not be cold, but comparable to room temperature. Typically, a standard syringe, pen or insulin pump is used to administer it, injecting subcutaneously, but under some conditions intravenous infusion is also allowed.

Subcutaneous injections are carried out mainly in the thigh, shoulder, abdomen or buttocks, alternating injection sites so that the same one is used no more than once a month. You need to be careful not to get into a vein, and it is also strictly not recommended to massage the skin in the area of the injection after it has been made. Humalog, purchased in the form of a cartridge for a pen, is used in the following order:

you need to wash your hands with warm water and choose a place for the injection;
the skin in the injection area is disinfected with an antiseptic;
the protective cap is removed from the needle;
the skin is fixed manually by pulling or pinching so that a fold is formed;
a needle is inserted into the skin, a button on the syringe pen is pressed;
the needle is removed, the injection site is gently pressed for a few seconds (without massaging or rubbing);
Using the protective cap, the needle is turned away and removed.

All these rules also apply to such varieties of the drug as Humalog Mix 25 and Humalog Mix 50, produced in the form of a suspension. The difference lies in the appearance and preparation of different types of medicine: the solution must be colorless and transparent, while it is immediately ready for use, while the suspension must be shaken several times so that the cartridge contains a homogeneous cloudy liquid, similar to milk.

Intravenous administration of Humalog is carried out in a clinical setting using a standard infusion system, where the solution is mixed with a 0.9% sodium chloride solution or a 5% dextrose solution. The use of insulin pumps for the administration of Humalog is organized according to the instructions included with the device. When performing injections of any type, you need to remember how much 1 unit of insulin reduces sugar in order to correctly assess the dose and reaction of the body. On average, this figure is 2.0 mmol/l for most insulin preparations, which is also true for Humalog.

Interaction with other drugs

The drug interactions of Humalog with other drugs are generally consistent with its analogues. Thus, the hypoglycemic effect of the solution will be reduced when combined with oral contraceptives, glucocorticosteroids, thyroid hormones, a number of diuretics and antidepressants, as well as nicotinic acid.

At the same time, the hypoglycemic effect of this insulin will increase when combined with therapy using:

beta blockers;
ethanol and drugs based on it;
anabolic steroids;
oral hypoglycemic agents;
sulfonamides.

Storage conditions and periods

Humalog should be stored out of the reach of children inside a regular refrigerator, at a temperature of +2 to +8 degrees Celsius. The standard shelf life is two years. If the package has already been opened, this insulin must be kept at room temperature from +15 to +25 degrees Celsius.

Care should be taken to ensure that the drug is not heated or placed in direct sunlight. Once used, the shelf life is reduced to 28 days.

Analogues

Direct analogues of Humalog should be considered all insulin preparations that act on the diabetic body in a similar way. Among the most famous brands are Actrapid, Vosulin, Gensulin, Insugen, Insular, Humodar, Isofan, Protafan and Homolong.